NTLA FY 2020 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$58M+34.5% YoY

Gross Profit

-$92M-159.4% margin

Operating Income

-$137M-235.5% margin

Net Income

-$134M-231.5% margin

EPS (Diluted)

$-2.40

Cash Flow

Operating Cash Flow

-$50M

Free Cash Flow

-$53M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$676M

Total Liabilities

$149M

Stockholders' Equity

$527M

Cash & Equivalents

$160M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$58M	$43M	+34.5%
Gross Profit	-$92M	-$65M	-41.5%
Operating Income	-$137M	-$106M	-28.4%
Net Income	-$134M	-$100M	-34.9%